AIM: To investigate the efficacy of anti-vascular endothelial growth factor(VEGF)drugs in the treatment of choroidal neovascularization(CNV)and its effects on intraocular pressure, best corrected visual acuity(BCVA)and multifocal electroretinogram(mfERG).

METHODS:Totally 44 cases(44 eyes)of idiopathic CNV patients treated in our hospital from February 2015 to January 2017 were selected. All patients were treated with intravitreal injection of anti-VEGF. BCVA, intraocular pressure, mfERG and central retinal thickness(CRT)were observed after treatment.

RESULTS: At 1 and 3mo after treatment, BCVA and CRT were significantly improved than those before treatment(P<0.05). At 3mo after treatment BCVA and CRT were 0.60±0.15 and 278.43±40.10μm, both significantly lower than that in 1mo after treatment(P<0.05). There was no significant change in intraocular pressure at 1 or 3mo after treatment than before treatment(P>0.05). At 1 and 3mo after treatment, amplitudes of Ring1, Ring2 and Ring4 NI-P1 were higher than those before treatment(P<0.05); at 3mo after treatment, the amplitude of Ring3 NI-P1 were higher than those before and 1mo after treatment(P<0.05); at 1mo after treatment, the amplitude of Ring5 NI-P1 were higher than those before and 3mo after treatment(P<0.05). The amplitude of Ring6 NI-P1 did not change significantly at 1 and 3mo after treatment, compared with before treatment(P>0.05).

CONCLUSION: Anti-VEGF drugs are effective in the treatment of idiopathic CNV, which can improve vision and macular retinal function, decrease the retinal thickness, and do not affect the intraocular pressure.